Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis by Yeo, L. et al.
 
 
Expression of chemokines CXCL4 and CXCL7 by
synovial macrophages defines an early stage of
rheumatoid arthritis
Yeo, Lorraine; Adlard, Nichola; Biehl, M.; Juarez, Maria; Smallie, Timothy; Snow, M.; Buckley,
Christopher; Raza, Karim; Filer, Andrew; Scheel-Toellner, Dagmar
DOI:
10.1136/annrheumdis-2014-206921
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Yeo, L, Adlard, N, Biehl, M, Juarez, M, Smallie, T, Snow, M, Buckley, CD, Raza, K, Filer, A & Scheel-toellner, D
2015, 'Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of
rheumatoid arthritis', Annals of the Rheumatic Diseases, pp. 763-771. https://doi.org/10.1136/annrheumdis-
2014-206921
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository : checked 20/04/2015
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
EXTENDED REPORT
Expression of chemokines CXCL4 and CXCL7 by
synovial macrophages deﬁnes an early stage of
rheumatoid arthritis
L Yeo,1 N Adlard,1 M Biehl,2 M Juarez,1 T Smallie,1 M Snow,3 C D Buckley,1
K Raza,1,4 A Filer,1,5 D Scheel-Toellner1
Handling editor Tore K Kvien
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
annrheumdis-2014-206921).
1Rheumatology Research
Group, Centre for Translational
Inﬂammation Research, College
of Medical and Dental
Sciences, University of
Birmingham, Birmingham, UK
2Johann Bernoulli Institute for
Mathematics and Computer
Science, University of
Groningen, University of
Groningen, Groningen, The
Netherlands
3Royal Orthopaedic Hospital
NHS Foundation Trust,
Birmingham, UK
4Sandwell and West
Birmingham Hospitals NHS
Trust, Birmingham, UK
5University Hospitals
Birmingham NHS Foundation
Trust, Birmingham, UK
Correspondence to
Dr D Scheel-Toellner,
Rheumatology Research Group,
Centre for Translational
Inﬂammation Research, College
of Medical and Dental
Sciences, University of
Birmingham, Birmingham -B15
2TT, UK; d.scheel@bham.ac.uk
LY, NA, KR, AF and DS-T
contributed equally.
Received 31 October 2014
Revised 18 February 2015
Accepted 7 March 2015
To cite: Yeo L, Adlard N,
Biehl M, et al. Ann Rheum
Dis Published Online First:
[please include Day Month
Year] doi:10.1136/
annrheumdis-2014-206921
ABSTRACT
Background and objectives For our understanding
of the pathogenesis of rheumatoid arthritis (RA), it is
important to elucidate the mechanisms underlying early
stages of synovitis. Here, synovial cytokine production
was investigated in patients with very early arthritis.
Methods Synovial biopsies were obtained from
patients with at least one clinically swollen joint within
12 weeks of symptom onset. At an 18-month follow-up
visit, patients who went on to develop RA, or whose
arthritis spontaneously resolved, were identiﬁed. Biopsies
were also obtained from patients with RA with longer
symptom duration (>12 weeks) and individuals with no
clinically apparent inﬂammation. Synovial mRNA
expression of 117 cytokines was quantiﬁed using PCR
techniques and analysed using standard and novel
methods of data analysis. Synovial tissue sections were
stained for CXCL4, CXCL7, CD41, CD68 and von
Willebrand factor.
Results A machine learning approach identiﬁed
expression of mRNA for CXCL4 and CXCL7 as
potentially important in the classiﬁcation of early RA
versus resolving arthritis. mRNA levels for these
chemokines were signiﬁcantly elevated in patients with
early RA compared with uninﬂamed controls.
Signiﬁcantly increased CXCL4 and CXCL7 protein
expression was observed in patients with early RA
compared with those with resolving arthritis or longer
established disease. CXCL4 and CXCL7 co-localised with
blood vessels, platelets and CD68+ macrophages.
Extravascular CXCL7 expression was signiﬁcantly higher
in patients with very early RA compared with longer
duration RA or resolving arthritis
Conclusions Taken together, these observations
suggest a transient increase in synovial CXCL4 and
CXCL7 levels in early RA.
INTRODUCTION
The rheumatoid synovium is characterised by a
complex inﬂammatory inﬁltrate, which can either
be highly structured with distinct features of lymph-
oid neogenesis or comprise a more diffuse inﬁltrate.
There is considerable evidence that cytokines pro-
duced by the synovial inﬁltrate play an important
role in the orchestration of both the development
and the resolution of synovial inﬂammation.1 Since
there is evidence that therapeutic outcome in
rheumatoid arthritis (RA) is inﬂuenced by the time
elapsed before initiation of therapy, there is a con-
siderable clinical need to diagnose patients with
early disease.2–4 Due to the important role of cyto-
kines in the regulation of the inﬂammatory inﬁltrate
and the need to understand and diagnose early RA,
this study systematically addresses the level of
mRNA expression of a wide range of cytokines in
the early stages of synovial inﬂammation.
In order to capture a population of patients in a
time frame close to the onset of clinically apparent
joint inﬂammation, patients with at least one clinic-
ally swollen joint were seen within 12 weeks of the
onset of any symptom attributed, by the assessing
rheumatologist, to an inﬂammatory arthritis. At this
time, among a range of other investigations per-
formed within the Birmingham Early Inﬂammatory
Arthritis Cohort (BEACON), ultrasound-guided
biopsies were taken. At an 18-month follow-up visit,
patients who had progressed to RA as classiﬁed
according to the 1987 American College of
Rheumatology (ACR) criteria5 or had resolving
disease were identiﬁed for this study. Furthermore,
patients from the same clinic who were disease-
modifying antirheumatic drug (DMARD) naive but
had synovitis for >12 weeks, as well as patients
attending a clinic due to mechanical joint problems
without any clinically observed inﬂammation, were
investigated as control groups.
Proﬁling of cytokine mRNA expression led to
the ﬁnding that the chemokines CXCL4 and
CXCL7 are expressed during the earliest phase of
RA, but not in patients with resolving arthritis or
established RA. We found that both chemokines,
which are classically regarded as platelet-derived
chemokines, were also expressed on macrophages
in the synovium, implicating a previously unde-
scribed role for this cell type in the earliest clinic-
ally evident stages of RA.
PATIENTS AND METHODS
Study participants
Patients with early arthritis were seen in the
BEACON cohort; details of this clinic have been
reported previously.6 Patients were eligible for the
early arthritis cohort if they had at least one clinic-
ally swollen joint, were seen within 12 weeks of the
onset of any symptom attributed by the assessing
rheumatologist to an inﬂammatory arthritis and had
not been treated with either DMARD or glucocorti-
coids prior to referral. Patients underwent a 68-joint
clinical examination.7 Patients with a joint amenable
to ultrasound-guided biopsy8 were recruited for this
study. Following the biopsy, patients were followed
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for up to 18 months. Patients were identiﬁed for inclusion in the
study if they were classiﬁed as having RA according to 1987 ACR
criteria,5 or a resolving arthritis deﬁned as the absence of clinic-
ally apparent synovial swelling at ﬁnal assessment with no
DMARDs or glucocorticoids having been used for the previous
three months. A small number of patients developed chronic
inﬂammatory diseases of the joint other than RA (table 1). As a
control group, we included patients with RA with disease dur-
ation (deﬁned as the time from the onset of any symptom attribu-
ted by the assessing rheumatologist to an inﬂammatory arthritis)
of >12 weeks who fulﬁlled the 1987 ACR criteria5 at the time of
biopsy. Similarly to patients with early arthritis, those with RA of
>12 weeks’ duration were all DMARD and glucocorticoid naive
and synovial tissue was obtained by ultrasound-guided biopsy. As
a further control group, we included ‘uninﬂamed controls’ who
underwent knee arthroscopy because of unexplained joint pain.
None of these subjects showed inﬂammatory or degenerative
joint pathology upon physical examination or arthroscopy. All
researchers involved in the investigation of biopsies either at
mRNA or protein level were blinded to patient outcome
throughout the study.
Ultrasound-guided synovial biopsy
Prior to biopsy, joints were assessed using a Siemens Acuson
Antares scanner (Siemens, Bracknell, UK) and multifrequency
(5–13 MHz) linear array transducers; for details, see Filer et al.7
Ultrasound-guided biopsy was used to collect tissue from mul-
tiple regions within knee, ankle or metacarpophalangeal (MCP)
joints in which there was evidence of grey-scale synovitis.
Ultrasound guidance was used to introduce a single portal
through which tissue was sampled using custom manufactured
2.0 mm cutting-edged forceps or a 16 g core biopsy needle
(MCP joint).9 Frozen blocks were assembled for processing
from six individual biopsies in order to overcome synovial het-
erogeneity.8 10–12
Synovial tissue cytokine mRNA real-time PCR analysis
TaqMan low-density real-time PCR arrays (Applied Biosystems,
Paisley, UK) were designed to determine expression of 117 cyto-
kines and cytokine-related molecules (for full details, see online
supplementary table S1). RNA was extracted from synovial
tissue sections using an RNeasy RNA extraction kit (Qiagen,
Crawley, UK). RNA from synovial tissue used in the low-density
array for genes with non-intron spanning primers was treated
with DNase (Qiagen). A reaction mixture containing RNA,
QuantiTect-RT Master Mix (Qiagen) and QuantiTect Reverse
Transcriptase (Qiagen, Crawley, UK) was added to a TaqMan
low-density array microﬂuidic card. Six times more RNA was
loaded into microﬂuidic cards designed for weakly expressed
genes and genes with non-intron spanning primers (see online
supplementary table S1). Reverse transcription and real-time
PCR was performed in a 7900HT Real-Time PCR System
(Applied Biosystems). Relative gene expression (RQ) was
expressed as 2−ΔCt, where ΔCt represents the difference in Ct
between glyceraldehyde-3-phosphate dehydrogenase and the
target gene. Validation experiments established the reproducibil-
ity of quantitation and a combination of positive controls from
anti-CD3/anti-CD28-activated lymphocytes and commercially
available control mRNA from human cell lines representing dif-
ferent tissues (Stratagene) were used to ascertain that all cyto-
kines listed could be detected.
GMLVQ analysis of cytokine mRNA proﬁles
Cytokine mRNA data were log-transformed and all zero values
were replaced by 0.00002, the smallest non-zero expression
value in the data. This yielded 117 log-transformed expression
values per patient. These data were analysed by applying a com-
bination of principal component analysis and learning vector
quantisation (LVQ), a distance-based classiﬁcation technique,
which determines class representatives from a set of example
data in an iterative training process. Example data corresponded
to the individual cytokine proﬁles observed within the four
classes of patients. Matrix relevance LVQ identiﬁes a suitable
distance measure, which is discriminative with respect to the dif-
ferent classes. The speciﬁc technique used was generalised
matrix relevance LVQ (GMLVQ), a variant that optimises the
distance measure with respect to its discriminative power.13
Further details on this methodology can be found in online sup-
plementary method 1.
Immunoﬂuorescence
Frozen sections from synovial biopsies taken from patients with
resolving arthritis, early RA and established RA were stained
with antibodies speciﬁc for CXCL4 (Abcam, UK) or CXCL7
Table 1 Demographic and clinical characteristics of study participants used for cytokine and chemokine mRNA real-time PCR low-density arrays
Uninflamed Resolving arthritis Early RA Established RA
Number 10 9 17 12
Symptom duration (weeks); median (IQR) na 5 (2–9) 6 (4–9) 38 (27–52)
Female; n (%) 5 (50) 3 (33) 12 (71) 6 (50)
Age years; median (IQR) 43 (37–48) 40 (30–69) 53 (48–59) 60 (48–67)
RF and/or anti-CCP positive; n (%) na 0 (0) 8 (47) 7 (58)
Global disease-related variables
CRP; median (IQR) na 10 (8–22) 12 (5–32) 17 (7–52)
ESR; median (IQR) na 24 (8–48) 25 (14–58) 28 (12–55)
DAS28; median (IQR) na 4.1 (3.4–4.6) 4.7 (4.2–6.0) 5.4 (4.7–6.6)
Biopsied joint-related variables
Joint biopsied
Ankle; n (%) 0 (0) 3 (33.3) 4 (24) 2 (17)
Knee; n (%) 10 (100) 6 (66.6) 10 (59) 10 (83)
MCP joint; n (%) 0 (0) 0 (0) 3 (18) 0 (0)
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; na, not available;
RF, rheumatoid factor.
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(Novus Biologicals, UK), and CD41 (Dako, UK), CD68
(Thermo Scientiﬁc Pierce, UK) and von Willebrand factor
(vWF) (Dako, UK). Staining with isotype-matched, species-
matched and concentration-matched negative controls was per-
formed in parallel. Secondary antibodies used were goat antirab-
bit Chromeo 494 (Abcam, UK), Cy3-conjugated streptavidin
( Jackson Immunoresearch, USA), goat antimouse Alexa Fluor
488 ( Jackson Immunoresearch, USA) and goat antimouse Cy5
(Southern Biotechnology, USA). Immunoﬂuorescence was visua-
lised using a Zeiss LSM 780 Zen Confocal and analysed using
Zeiss imaging software (Zeiss, Germany). Five to six 2×2 tile
scans were taken from each section at ×400 total magniﬁcation.
Regions were drawn around tissue; areas with folding or bleed-
ing into tissue caused during biopsy collection/processing were
excluded from analysis. As readout, pixels per unit area were
calculated.
RESULTS
Study participants
Details of study participants used for cytokine mRNA proﬁling
and immunoﬂuorescence studies are shown in tables 1 and 2,
respectively. The symptom durations of patients with early arth-
ritis highlight that this population was captured very soon after
the onset of their clinically apparent disease (median 5 weeks
for those with resolving disease and 6 weeks for those with
early RA in the patients who provided samples for cytokine
mRNA proﬁling; median 6 weeks for those with resolving
disease and 7 weeks for those with early RA in the patients who
provided samples for immunoﬂuorescence studies).
Synovial cytokine mRNA expression proﬁles in early arthritis
The mRNA expression of a panel of 117 cytokines and related
molecules was assessed in synovial biopsies using low-density
real-time PCR arrays. Subject groups investigated were patients
with resolving arthritis (n=9), patients with very early RA
(n=17), patients with established RA (>3 months’ symptom
duration; n=12) and uninﬂamed control subjects (n=10).
Twenty-two genes were identiﬁed as being differentially
expressed between subject groups by Kruskal–Wallis and Dunn’s
post-test analysis, shown in ﬁgure 1A. Eighteen of these genes
were more highly expressed in patients with established RA
compared with the uninﬂamed controls. Of interest, both
CXCL4 and CXCL7 mRNA levels were found to be signiﬁcantly
elevated in patients with early RA compared with uninﬂamed
controls, and showed a trend towards higher expression in early
RA compared with patients with resolving arthritis. Intriguingly
there was also a trend towards higher expression in early RA
compared with established RA, suggesting an increase in CXCL4
and CXCL7 levels in the early phase of disease in patients whose
arthritis persisted versus those whose arthritis resolved. No sig-
niﬁcant differences were observed in CXCL4 and CXCL7
expression between cyclic citrullinated peptide (CCP)-positive
and CCP-negative patients in either the early RA or established
RA groups (see online supplementary ﬁgure S2). When cytokine
and chemokine mRNA expression was ranked by their difference
in expression between resolving arthritis and early RA groups,
CXCL4 and CXCL7 were ranked highly in showing differential
expression between the two groups (ﬁgure 1B).
Machine learning classiﬁcation selection of differentiating
cytokines and chemokines
We applied a novel strategy of multivariate analysis to test
whether combinations of gene expression signals rather than
individual cytokine mRNA signals could distinguish synovium
from patients with self-limiting arthritis from those with early-
stage RA. Matrix relevance GMLVQ analysis was applied to
the cytokine mRNA data to achieve classiﬁcation of samples by
determining a discriminative distance measure that characterises
differences between subject groups. For classiﬁcation of the
established RA and uninﬂamed groups, analysis of the obtained
relevance matrix revealed that the 10 most informative
genes in discriminating patients with established RA from unin-
ﬂamed controls were CXCL7, CXCL4, IL1B, MST1, CCL20,
IL8, LGALS12, LTA, CXCL13 and OSM (ﬁgure 2A). Receiver-
operating characteristic (ROC) analysis was used to assess the
performance of classiﬁer models for group classiﬁcation. For
the established RA and uninﬂamed group classiﬁcation,
GMLVQ yielded an area under the curve (AUC) of 0.996
(ﬁgure 2B). For classiﬁcation of the early RA and resolving
arthritis groups, the 10 most informative genes corresponded
to CXCL7, CXCL4, MST1, CCL20, LGALS12, IL8, IL1B,
CXCL1, LTA and IL1RN (ﬁgure 2C). ROC analysis yielded
Table 2 Demographic and clinical characteristics of study participants used for detection of CXCL4 and CXCL7 by immunofluorescence
Resolving arthritis Early RA Established RA Early non-RA
Number 9 10 11 5
Symptom duration (weeks); median (IQR) 6 (3–7) 7 (4.8–9.3) 45 (16–53) 7 (2–8.5)
Female; n (%) 3 (33) 5 (50) 6 (55) 2 (40)
Age, years; median (IQR) 37 (33–65) 58 (50–65) 62 (57–65) 41 (37–56)
RF and/or anti-CCP positive; n (%) 0 (0) 4 (40) 6 (55) 1 (20)
Global disease-related variables
CRP; median (IQR) 8 (3–13.5) 26 (7.5–58) 10 (0–79) 25 (18.5–54)
ESR; median (IQR) 18 (5.5–51) 19 (4.75–39.25) 50 (34–70) 44 (24–73.5)
DAS28; median (IQR) 4.1 (3.4–5.7) 4.7 (3.8–5.8) 5.2 (4.6–7.5) 4.8 (4.1–6.4)
Biopsied joint-related variables
Joint biopsied
Ankle; n (%) 2 (22) 2 (20) 3 (27) 2 (40)
Knee; n (%) 7 (78) 7 (70) 8 (73) 3 (60)
MCP joint; n (%) 0 (0) 1 (10) 0 (0) 0 (0)
Early non-RA group: psoriatic arthritis n=2, sarcoidosis n=1, ankylosing spondylitis n=1, unclassified n=1.
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; na, not available;
RF, rheumatoid factor.
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an AUC of 0.764 (ﬁgure 2D). In both cases, CXCL4
and CXCL7 played dominant roles in terms of discriminative
power.
CXCL4 and CXLC7 protein expression in synovial tissue
Since cytokine mRNA proﬁling suggested an upregulation of
CXCL4 and CXCL7 expression in patients with early RA, we
Figure 1 Cytokine and chemokine mRNA expression in synovial biopsies from uninﬂamed controls and patients with resolving arthritis, early
rheumatoid arthritis (RA) and established RA. (A) Synovial tissue sections were assessed from uninﬂamed controls (n=10) and patients with
resolving arthritis (n=9), early RA (n=17) and established RA (n=12). Data for genes for which the Kruskal–Wallis and Dunn’s post-test showed
signiﬁcant difference between the four groups are shown. * p<0.05, ** p<0.01, ***p<0.001. (B) Cytokine and chemokine genes were ranked by
difference in mRNA expression between resolving arthritis and early RA groups. Means of each group are represented in the heat map. Green
represents low and red high relative expression (z-score of mean expression levels).
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next sought to test whether expression of these chemokines was
also elevated at the protein level. CXCL4 and CXCL7
were stained in synovial tissue sections from patients with
resolving arthritis (n=9), early RA (n=10) and established RA
(n=11), and staining was visualised by immunoﬂuorescence.
Representative images of staining of CXCL4 and CXCL7 in the
synovium are shown in ﬁgure 3A, B. Synovial tissue sections
were co-stained for CD68 to identify macrophages, CD41 to
identify platelets and vWF to identify vascular endothelial cells.
Both CXCL4 and CXCL7 were found to be expressed in the
synovium of all subject groups examined. However, expression
of both CXCL4 and CXCL7 was signiﬁcantly elevated in
patients with early RA compared with patients with resolving
arthritis (CXCL4 and CXCL7; p<0.05) and patients with estab-
lished RA (CXCL4 and CXCL7; p<0.05; ﬁgure 3C), which
supported the ﬁndings made at the mRNA level. Quantiﬁcation
of protein levels of CD41, which is speciﬁcally expressed by pla-
telets, did not show signiﬁcant differences (data not shown).
The groups of patients investigated in the cytokine mRNA pro-
ﬁling and those tested for immunoﬂuorescence studies were par-
tially overlapping. Protein data from seven patients who were
not investigated in the mRNA study also showed a higher level
of CXCL4 and CXCL7 protein expression in the patients with
early RA compared with those with established disease (see
online supplementary ﬁgure S3A and B). A small number of
patients developed chronic inﬂammatory joint diseases other
than RA (table 2). Their CXCL4 and CXCL7 levels are shown
in online supplementary ﬁgures S3C, D.
In the synovium of all subject groups studied, CXCL4 and
CXCL7 staining was found to co-localise with CD68 staining,
indicating an association of both of these chemokines with
macrophages (ﬁgure 4A, B). As expected, CXCL4 and CXCL7
staining was also observed on CD41-expressing platelets
(ﬁgure 3). To further investigate this ﬁnding, synovial tissue
samples were stained for vWF and expression of CXCL4 and
CXCL7 was quantiﬁed inside and outside of the vasculature.
Quantiﬁcation of positive pixels showed that CXCL4 and
CXCL7 were found predominantly outside the vasculature
(ﬁgure 5A, B). In addition, the speciﬁcity of the CXCL7 staining
was conﬁrmed by inhibition of staining with preincubation of the
antibody with recombinant CXCL7 (see online supplementary
ﬁgure S1).
Figure 2 Generalised matrix relevance learning vector quantisation-based discrimination of subject groups (A) All 117 cytokine/chemokine genes
used to classify uninﬂamed controls versus patients with established rheumatoid arthritis (RA). The 10 genes most informative in discriminating
groups are indicated. (B) Receiver-operating characteristic (ROC) characteristics of the obtained classiﬁers for uninﬂamed controls and patients with
established RA. (C) Classiﬁcation cytokine mRNA signals in resolving arthritis versus patients with early RA. The 10 genes most informative in
discriminating groups are indicated. (D) ROC characteristics of the obtained classiﬁers for patients with resolving arthritis and early RA. AUC, area
under the curve.
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DISCUSSION
In this study, we have identiﬁed two chemokines, CXCL4 and
CXCL7, which are expressed in the earliest clinically apparent
stage of RA. They were predominantly detected on macrophages
inﬁltrating the synovium, indicating a previously undescribed
role for this cell type in contributing to RA pathogenesis in the
very early phase of disease.
Macrophages are found in large numbers throughout the
rheumatoid synovium. Type A synoviocytes are macrophage-
derived cells that constitute part of the healthy synovial lining
while large numbers of activated macrophages are found in the
inﬂammatory inﬁltrate in the sublining and at the pannus–
cartilage interface. The origin of these cells is a matter of
debate; they could derive from the proliferation of tissue-based
macrophages or from circulating monocytes entering from the
blood stream.14–17 Macrophages are important contributors to
inﬂammation and joint destruction due to their production of
proinﬂammatory mediators and tissue-degrading enzymes.
Figure 3 Immunoﬂuorescence staining of CXLC4 and CXCL7 in synovial tissue sections. (A) Synovial tissue staining of CXCL4 (red), CD68 (blue),
CD41 (green) and von Willebrand factor (vWF) (orange). (B) Synovial tissue staining of CXCL7 (red), CD68 (blue), CD41 (green) and vWF (orange).
Nuclear counterstain is shown. Images are representative of early rheumatoid arthritis (RA) synovium (n=10). No staining was observed using
isotype and concentration-matched negative controls. Images were taken at ×40 magniﬁcation. (C) Quantiﬁcation of CXCL4 and CXCL7 staining,
calculated as the number of pixels per μm2 over 6× 2×2 tile scans at ×40 magniﬁcation, in synovial tissue sections from patients with resolving
arthritis (n=9), early RA (n=10) and established RA (n=11). Patients with early RA showed a signiﬁcantly higher level of CXCL4 (p<0.05) and CXCL7
(p<0.05) compared with patients with resolving arthritis and established RA. Kruskal–Wallis and Dunn’s post-test; * p<0.05, ** p<0.01.
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Furthermore, the number of synovial macrophage has been
found to correlate with joint erosion in RA while changes in the
numbers of CD68+ macrophages correlate with therapeutic
success of a range of therapies.18–20
CXCL4 is chemotactic for neutrophils, ﬁbroblasts and mono-
cytes, prevents monocyte apoptosis, induces differentiation of
monocytes into macrophages and enhances monocyte phagocyt-
osis and oxygen radical production.21–24 CXCL7 is involved in
neutrophil chemotaxis and activation, and activates connective
tissue cells.25 The functions described for CXCL4 and CXCL7
suggest that in RA these chemokines could not only exacerbate
synovial inﬂammation but also promote its chronicity by attract-
ing monocytes to the inﬂamed tissue and activating them fol-
lowing recruitment to the synovium. Our ﬁnding that CXCL4
and CXCL7 are highly expressed during the ﬁrst 12 weeks of
synovitis in patients who develop RA but are found at lower
levels in longer duration RA may reﬂect local pathological
changes occurring during this critical phase, which has been
described as the therapeutic ’window of opportunity’. A similar
phenomenon was recently reported by van Bon et al,26 who
demonstrated high levels of CXCL4 expression in patients at an
early stage of systemic sclerosis.
Previous studies have suggested roles for CXCL4 and CXCL7
in RA. Elevated levels of CXCL7 have been reported in the
serum, synovial ﬂuid and synovial tissue of patients with
RA.27 28 While CXCL7 promotes angiogenesis, CXCL4 has an
antiangiogenic effect.29 The elevated expression of the angio-
static chemokine CXCL4 during the early phase of disease may
reﬂect an attempt to prevent or minimise the ﬁrst signs of angio-
genesis that takes place in the RA synovium.
In our study, CXCL4 and CXCL7 expression in the synovium
was found to be predominantly localised to CD68+ macro-
phages, with less co-localisation observed with platelets. Where
CXCL4 and CXCL7 expression was seen to co-localise with pla-
telets in the synovium, this was mainly conﬁned to vessel
thrombi. The genes for CXCL4 and CXCL7 are located in a
Figure 4 Co-localisation of CXCL4 and CXCL7 with CD68-positive cells. (A) Synovial tissue staining of CXCL4 (red) and CD68 (blue) and (B)
staining of CXCL7 (red) and CD68 (blue) showed co-localisation of both cytokines with macrophages. Image representative of rheumatoid arthritis
synovium (n=10).
Figure 5 Expression of CXCL4 and CXCL7 in the synovium is predominantly found outside the vasculature. Staining of CXCL4 and CXCL7 in
synovial tissue sections was quantiﬁed inside and outside of the vasculature, as assessed by co-staining with von Willebrand factor. Expression of
both chemokines was signiﬁcantly elevated outside the vasculature. RA, rheumatoid arthritis. Kruskal–Wallis test, Dunn’s post-test; *p<0.05,
***p<0.001.
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gene cluster comprising several CXC chemokines in a locus on
chromosome 4,30 31 which was once considered to be
megakaryocyte-speciﬁc. However, other studies have reported
that expression of these chemokines is not restricted to the
megakaryocyte lineage. A recent study using a PF4-Cre mouse
model reported that CXCL4 could be produced by both
myeloid and lymphoid lineages, with CXCL4 transcripts
detected in adult haematopoietic stem cells.32 In a similar
reporter gene model, CXCL4 expression was shown in mature
murine macrophages.33 Furthermore, Schaffner et al34 reported
expression of CXCL4 by human monocytes and found that
CXCL4 expression was upregulated upon monocyte activation.
Intriguingly, a recent study reported CXCL4 expression by acti-
vated T cells that limited Th17 differentiation.35 Monocytes
have been described to constitutively transcribe and translate
CXCL7, which is processed intracellularly into several deriva-
tives known to have signalling and effector functions.36
Together this evidence is supportive of our ﬁnding that CXCL4
and CXCL7 is associated with and may be produced directly by
macrophages in the synovium during very early RA.
Interest in chemokines in RA has been revived by ﬁndings
such as detection of citrullinated chemokines in RA synovial
ﬂuid that have enhanced chemotactic activity37 and the prospect
of using antichemokine targeting for therapeutic purposes.38 39
We have interpreted the high levels of CXCL4 and CXCL7
found in early RA compared with resolving arthritis or estab-
lished RA to represent a transient upregulation of these cyto-
kines based on a cross-sectional analysis of samples; it would be
interesting to conﬁrm the transient nature of this upregulation
in a longitudinal study. However, the ethical implications would
make an observational study of the evolution of synovial tissue
pathology from early to established RA in the absence of
therapeutic intervention impossible to conduct in patients. In
the future, it will be important to investigate whether the pro-
duction of CXCL4 and CXCL7 observed in the synovium in
early RA is reﬂected by elevated levels in plasma samples. Future
use of these chemokines as biomarkers for prediction of pro-
gression to RA will depend on replication in other independent
cohorts.
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